Exelixis

This study is testing whether a combination of two drugs (cabozantinib and atezolizumab) works better than the current standard drug (sorafenib) for adults with advanced liver cancer who haven't had prior drug treatment. The main goals are to see if the combination helps patients…

This study is for men with advanced prostate cancer that has spread and is no longer responding well to standard hormone therapy. It compares a new two-drug combination (cabozantinib and atezolizumab) against a second round of standard hormone therapy. The main goals are to see i…

This study tested whether the drug cabozantinib could help control advanced thyroid cancer that no longer responds to radioactive iodine or certain targeted therapies. It involved 187 patients whose cancer had worsened despite previous treatment. Participants were randomly assign…

This study aims to see if a lower daily dose (60 mg) of the cancer drug cabozantinib works as well as the standard higher dose (140 mg) for people with advanced medullary thyroid cancer that is getting worse. Researchers want to find out if the lower dose can control the cancer f…

This study is testing whether a new two-drug combination (XL092 + atezolizumab) works better than the current standard drug (regorafenib) for people with advanced colorectal cancer that has spread and stopped responding to other treatments. It involves about 900 participants whos…

This large, late-stage trial is comparing a three-drug combination to the current standard two-drug treatment for people with advanced kidney cancer who haven't had prior therapy. The study aims to see if adding a third drug helps patients live longer without their cancer getting…